Annexon Management
Management criteria checks 4/4
Annexon's CEO is Doug Love, appointed in Dec 2014, has a tenure of 9.92 years. total yearly compensation is $2.45M, comprised of 24.2% salary and 75.8% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth $1.53M. The average tenure of the management team and the board of directors is 2.5 years and 6.1 years respectively.
Key information
Doug Love
Chief executive officer
US$2.5m
Total compensation
| CEO salary percentage | 24.2% |
| CEO tenure | 9.9yrs |
| CEO ownership | 0.3% |
| Management average tenure | 2.5yrs |
| Board average tenure | 6.1yrs |
Recent management updates
Recent updates
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely
Sep 27
Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS
Aug 17Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place
Jun 04Annexon: Unforced Error Sullies Prospects
Apr 03Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation
Nov 10Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
Jul 25Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
Apr 11Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?
Feb 14We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully
Dec 28Annexon started as a buy at Jefferies on market potential of candidates, data catalysts
Sep 16Annexon: A First Take
Aug 21Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02
Aug 08Annexon to raise $130M in stock and warrant offering
Jul 08We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate
Apr 16Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth
Jan 01Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth
Sep 08We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth
May 22We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth
Feb 06
Dosing underway in Annexon's Phase 2/3 study of monoclonal antibody in Guillain-Barré Syndrome
Dec 21Annexon Biosciences EPS misses by $0.43
Nov 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$118m |
| Jun 30 2024 | n/a | n/a | -US$115m |
| Mar 31 2024 | n/a | n/a | -US$121m |
| Dec 31 2023 | US$2m | US$593k | -US$134m |
| Sep 30 2023 | n/a | n/a | -US$141m |
| Jun 30 2023 | n/a | n/a | -US$143m |
| Mar 31 2023 | n/a | n/a | -US$145m |
| Dec 31 2022 | US$4m | US$569k | -US$142m |
| Sep 30 2022 | n/a | n/a | -US$145m |
| Jun 30 2022 | n/a | n/a | -US$145m |
| Mar 31 2022 | n/a | n/a | -US$140m |
| Dec 31 2021 | US$8m | US$534k | -US$130m |
| Sep 30 2021 | n/a | n/a | -US$116m |
| Jun 30 2021 | n/a | n/a | -US$103m |
| Mar 31 2021 | n/a | n/a | -US$84m |
| Dec 31 2020 | US$5m | US$446k | -US$70m |
| Sep 30 2020 | n/a | n/a | -US$56m |
| Jun 30 2020 | n/a | n/a | -US$45m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$3m | US$396k | -US$38m |
| Sep 30 2019 | n/a | n/a | -US$34m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | US$518k | US$379k | -US$18m |
Compensation vs Market: Doug's total compensation ($USD2.45M) is about average for companies of similar size in the US market ($USD2.18M).
Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.
CEO
Doug Love (56 yo)
9.9yrs
Tenure
US$2,453,184
Compensation
Mr. Douglas Love, Esq., J.D, also known as Doug, has been the President, Director and Chief Executive Officer of Annexon Inc. since December 2014. He has extensive business and legal leadership experience...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 9.9yrs | US$2.45m | 0.28% $ 1.5m | |
| Chief Scientific Officer & Executive VP | 1.8yrs | US$1.83m | 0.047% $ 258.7k | |
| Executive VP | 3.1yrs | US$1.14m | 0.067% $ 366.8k | |
| Executive VP | 5.4yrs | US$1.44m | 0.026% $ 141.5k | |
| Executive VP & Chief Business Officer | 4.3yrs | US$1.40m | 0.033% $ 183.4k | |
| Senior Vice President of Translational Medicine | no data | no data | no data | |
| Executive VP & Chief Medical Officer | 1.3yrs | no data | no data | |
| Senior VP & Head of Commercial | less than a year | no data | no data | |
| Senior VP of Medical Affairs | less than a year | no data | no data |
2.5yrs
Average Tenure
59.5yo
Average Age
Experienced Management: ANNX's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 9.9yrs | US$2.45m | 0.28% $ 1.5m | |
| Executive VP | less than a year | US$1.14m | 0.067% $ 366.8k | |
| Independent Director | 9.9yrs | US$103.93k | 0.76% $ 4.1m | |
| Independent Chairman | 7.8yrs | US$132.43k | 0.00025% $ 1.4k | |
| Independent Director | 4.4yrs | US$100.93k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$103.43k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
6.1yrs
Average Tenure
66yo
Average Age
Experienced Board: ANNX's board of directors are considered experienced (6.1 years average tenure).